Company profile: Monte Rosa Therapeutics
1.1 - Company Overview
Company description
- Provider of platforms and tools for protein degradation therapeutics, including the QuEEN Platform, the AI-driven Degron Encyclopedia, a proprietary molecular glue degrader (MGD) library, and the Glueomics Toolbox; advancing a pipeline of MGDs for cancer, autoimmune, and inflammatory diseases, with an expanded access policy for investigational drugs.
Products and services
- Pipeline: develops indication-specific molecular glue degraders targeting proteins in cancer, autoimmune, and inflammatory diseases, advancing programs from discovery toward therapeutics
- QuEEN Platform: architects a platform-scale discovery and development system that identifies disease-relevant protein targets and engineers high-potency, high-selectivity degraders to induce targeted protein degradation
- Proprietary MGD Library: curates a custom-engineered collection of molecular glue degraders designed to target and degrade disease-relevant proteins for precise therapeutic modulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Monte Rosa Therapeutics
Provision Healthcare
HQ: United States
Website
- Description: Provider of cancer care and proton therapy, offering the ProNova SC360 system (360° treatment with superconducting magnets), integrated dual-energy CBCT for IGRT, fast-scanning IMPT, an independent energy selection system for instantaneous room switching, SBRT, and ARC radiation therapy, with a focus on improving patient care, outcomes, research, education, and charitable causes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Provision Healthcare company profile →
Proteomedix
HQ: Switzerland
Website
- Description: Provider of blood-based prostate cancer diagnostics, notably Proclarix: a test panel that integrates biomarkers and patient data to compute a risk score for high-grade prostate cancer using samples taken for PSA testing. Clinical evidence from 955 subjects shows Proclarix reduces unnecessary biopsies by accurately detecting clinically significant cancer; offers biomarker signatures for diagnosis, prognosis, and therapy management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proteomedix company profile →
Seagen
HQ: United States
Website
- Description: Provider of monoclonal antibody-based therapies and advanced antibody-drug conjugate technology focused on improving patient outcomes in cancer and autoimmune diseases. Lead program SGN-35 is in a pivotal trial for patients with relapsed or refractory Hodgkin lymphoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seagen company profile →
Cero Therapeutics
HQ: United States
Website
- Description: Provider of cellular immunotherapy centered on a CER T-cell platform that integrates anti-tumor capabilities of the innate and adaptive immune systems into a single T cell, aimed at treating hematologic malignancies and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cero Therapeutics company profile →
Zap Surgical
HQ: United States
Website
- Description: Provider of the ZAP-X gyroscopic radiosurgery platform for treating brain tumors, lesions, and head and neck conditions, utilizing a modern linear accelerator that eliminates radioactive source replacements. Offers vault-free design to reduce infrastructure costs, dual independent gantries for >1000 non-coplanar beam angles, tungsten-shielded collimation, and SRS webinars and clinical publications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zap Surgical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Monte Rosa Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Monte Rosa Therapeutics
2.2 - Growth funds investing in similar companies to Monte Rosa Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Monte Rosa Therapeutics
4.2 - Public trading comparable groups for Monte Rosa Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →